ClinicalTrials.gg
RecruitingNCT05389046Updated Jan 17, 2024

Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

An interventional study of Escitalopram and Escitalopram+Aripiprazole in Outpatients / Inpatients With Depression, sponsored by Peking University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by Peking University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 7 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.

Planned enrollment
25th of 99
252 · median 80
Started
2022
with 5 others
No phase
17 of 100
3 open now
Registered
90th of 100
by date

Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 25th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2022, is one of 17 with no phase, and was the 90th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing escitalopram in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.

Read the detailed description

Major depressive disorder (MDD) is a heterogeneious psychiatric disorder with complex etiology and pathogenesis. The lack of objective criteria for diagnosis and the use of trial-and-error treatment strategy are the current challenge. Anhedonia is the core symptom of MDD and the aberrant reward system and abnormal inflammatory immune may be the pathological mechanisms. Previous evidence suggests anhedonia cannot be improved quickly and efficiently by taking the first-line antidepressants. This study focuses on exploring the optimal diagnosis and treatment strategy for MDD patients with anhedonia. Based on the hypothesis of inflammatory-immune system,neurotransmitter abnormalities and aberrant reward system, this study aims to evaluate the efficacy and safety of the combinations of escitalopram and aripiprazole and/or omega-3 polyunsaturated fatty acids for MDD patients with anhedonia with a factorial design. Moreover, the multidimensional data including the clinicopathological features, neuroimaging data (MRI) and inflammatory cytokines will be used to establish the model of diagnosis and treatment strategy.

03

Conditions studied

  • Outpatients / Inpatients With Depression

Keywords

  • major depressive disorder
  • anhedonia
  • inflammatory immune
  • reward system
  • optimal treatment
  • neurotransmitter
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Major depressive disorder according to (5th edition) (DSM-5);
  2. Age: 18-55 (including 18 and 55)
  3. HAMD-17≥18
  4. DARS ≤ 28
  5. Do not receive repetitive Transcranial Magnetic Stimulation (rTMS) or modified electroconvulsive therapy (MECT) treatment in past six months.
  6. Sign the form voluntarily and agree to participate in all visits, examinations and treatment as required by the trial protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are diagnosed with major somatic diseases;
  2. Patients who meet diagnostic criteria for other mental disorders: Personality disorder, mental retardation; drug and/or alcohol dependence;
  3. Patients with severe suicidal tendencies or suicidal behavior;
  4. Pregnant or lactating women;
  5. Patients with MRI ;
  6. Patients who are regarded as unsuitable by investigators for this clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Escitalopram

    Escitalopram monotherapy (10-20 mg/day)

    Drug: Escitalopram

  • Experimental
    Escitalopram + omega-3 PUFAs

    Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)

    Drug: Escitalopram+omega-3 PUFAs

  • Experimental
    Escitalopram + Aripiprazole

    Escitalopram (10-20 mg/day)combined with Aripiprazole (2.5-10 mg/day)

    Drug: Escitalopram+Aripiprazole

  • Experimental
    Escitalopram + omega-3 PUFAs + Aripiprazole

    Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)and Aripiprazole (2.5-10 mg/day)

    Drug: Escitalopram+Aripiprazole+omega-3 PUFAs

Interventions

06

What researchers measure

Primary outcomes

  1. 17-item Hamilton depression rating scale (HAMD-17) value

    The value of 17-item Hamilton depression rating scale (HAMD-17) total score treatment compared to that at the baseline. The maximum score of HAMD-17 is 51 and the minimum is 0. Higher scores mean a worse outcome.

    Time frame: Day 0 to Day 56

  2. Anhedonia level-Dimensional Anhedonia Rating Scale (DARS)

    The outcome is measured by Dimensional Anhedonia Rating Scale (DARS) total score. The maximum score of DARS total score is 68 and the minimum is 0. Higher scores mean a better outcome.

    Time frame: Day 0 to Day 56

Secondary outcomes

  1. Anxiety symptoms

    The outcome is measured by Hamilton anxiety rating scale (HAMA) total score change. The change value of HAMA total scores at each timepoints compared to the baseline. The maximum score of HAMA is 56 and the minimum is 0. Higher scores mean a worse outcome.

    Time frame: Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56

Other outcomes

  1. cognition outcome

    The outcome is measured by cognition task.

    Time frame: Day 0 to Day 56

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 28 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2022
First posted
May 24, 2022
StartActual
Aug 15, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05389046
Lead sponsor
Peking University
Responsible party
Si Tianmei (Professor, Peking University Sixth Hospital) — Principal investigator
First posted
May 24, 2022
Start date
Aug 15, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 17, 2024

Study contacts

Tian-Mei Si, Ph.D
Contact
sitianmei@bjmu.edu.cn
861062723748

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Escitalopram · Aripiprazole

Start the discussion